These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 31529232)

  • 1. Product Development, Manufacturing, and Packaging of Solid Dosage Forms Under QbD and PAT Paradigm: DOE Case Studies for Industrial Applications.
    Singh BN
    AAPS PharmSciTech; 2019 Sep; 20(8):313. PubMed ID: 31529232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality by design and process analytical technology for sterile products--where are we now?
    Riley BS; Li X
    AAPS PharmSciTech; 2011 Mar; 12(1):114-8. PubMed ID: 21181513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical quality by design: product and process development, understanding, and control.
    Yu LX
    Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approach to Establishment of Control Strategy for Oral Solid Dosage Forms Using Continuous Manufacturing.
    Ishimoto H; Kano M; Sugiyama H; Takeuchi H; Terada K; Aoyama A; Shoda T; Demizu Y; Shimamura J; Yokoyama R; Miyamoto Y; Hasegawa K; Serizawa M; Unosawa K; Osaki K; Asai N; Matsuda Y
    Chem Pharm Bull (Tokyo); 2021 Feb; 69(2):211-217. PubMed ID: 33298636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.
    Badawy SI; Narang AS; LaMarche KR; Subramanian GA; Varia SA; Lin J; Stevens T; Shah PA
    J Pharm Sci; 2016 Jan; 105(1):168-81. PubMed ID: 26852852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical product development: A quality by design approach.
    Pramod K; Tahir MA; Charoo NA; Ansari SH; Ali J
    Int J Pharm Investig; 2016; 6(3):129-38. PubMed ID: 27606256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Process Analytical Technology for Crystallization of Active Pharmaceutical Ingredients.
    Malwade CR; Qu H
    Curr Pharm Des; 2018; 24(21):2456-2472. PubMed ID: 29956616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it advantageous to use quality by design (QbD) to develop nanoparticle-based dosage forms for parenteral drug administration?
    Camacho Vieira C; Peltonen L; Karttunen AP; Ribeiro AJ
    Int J Pharm; 2024 May; 657():124163. PubMed ID: 38670473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A quality by design study applied to an industrial pharmaceutical fluid bed granulation.
    Lourenço V; Lochmann D; Reich G; Menezes JC; Herdling T; Schewitz J
    Eur J Pharm Biopharm; 2012 Jun; 81(2):438-47. PubMed ID: 22446063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of design space and quality by design methodologies combined with ultra high-performance liquid chromatography for the optimization of the sample preparation of complex pharmaceutical dosage forms.
    Yogendrarajah P; Natalis L; Peys W; Lenaerts M; Lebrun P; Boon JP; Hellings M
    J Pharm Biomed Anal; 2023 Apr; 227():115149. PubMed ID: 36827738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approach.
    Waghule T; Dabholkar N; Gorantla S; Rapalli VK; Saha RN; Singhvi G
    Biomed Pharmacother; 2021 Sep; 141():111940. PubMed ID: 34328089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of experiments (DoE) in pharmaceutical development.
    N Politis S; Colombo P; Colombo G; M Rekkas D
    Drug Dev Ind Pharm; 2017 Jun; 43(6):889-901. PubMed ID: 28166428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality by design (QbD) approaches in current pharmaceutical set-up.
    Mishra V; Thakur S; Patil A; Shukla A
    Expert Opin Drug Deliv; 2018 Aug; 15(8):737-758. PubMed ID: 30044646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scientific, statistical, practical, and regulatory considerations in design space development.
    Debevec V; Srčič S; Horvat M
    Drug Dev Ind Pharm; 2018 Mar; 44(3):349-364. PubMed ID: 29200316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT).
    Aksu B; De Beer T; Folestad S; Ketolainen J; Lindén H; Lopes JA; de Matas M; Oostra W; Rantanen J; Weimer M
    Eur J Pharm Sci; 2012 Sep; 47(2):402-5. PubMed ID: 22749874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality by Design: Concept to Applications.
    Swain S; Parhi R; Jena BR; Babu SM
    Curr Drug Discov Technol; 2019; 16(3):240-250. PubMed ID: 29521238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding pharmaceutical quality by design.
    Yu LX; Amidon G; Khan MA; Hoag SW; Polli J; Raju GK; Woodcock J
    AAPS J; 2014 Jul; 16(4):771-83. PubMed ID: 24854893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward Higher QA: From Parametric Release of Sterile Parenteral Products to PAT for Other Pharmaceutical Dosage Forms.
    Hock SC; Constance NX; Wah CL
    PDA J Pharm Sci Technol; 2012; 66(4):371-91. PubMed ID: 22767885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Question-based review for pharmaceutical development: An enhanced quality approach.
    Simões A; Veiga F; Vitorino C
    Eur J Pharm Biopharm; 2024 Feb; 195():114174. PubMed ID: 38160986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).
    Cook G; France G; Holte Ø; Lorenti G; Tainsh D
    PDA J Pharm Sci Technol; 2016; 70(2):163-76. PubMed ID: 26797977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.